US Patent

US11497711 — Film formulations containing dexmedetomidine and methods of producing them

Method of Use · Assigned to ARx LLC · Expires 2039-06-26 · 13y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a self-supporting, dissolvable film containing dexmedetomidine or a pharmaceutically acceptable salt thereof for oral transmucosal delivery.

USPTO Abstract

Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Drugs covered by this patent

chembl-chembl2106195 (DEXMEDETOMIDINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3645`	—	chembl-chembl2106195
`U-3645`	—	chembl-chembl2106195

Patent Metadata

Patent number: US11497711
Jurisdiction: US
Classification: Method of Use
Expires: 2039-06-26
Drug substance claim: No
Drug product claim: Yes
Assignee: ARx LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.